He has 30 years of experience in discovery, development, and global commercialisation of biopharmaceuticals, involving over 10 FDA approved biologics at a series of successful biotechnology companies. Most recently John helped lead Adnexus from a start-up to the $450M acquisition by BMS within 4 years, where he then continued with the company for next 3 years serving as President. Prior to joining Adnexus, John was Vice President of Sales, Marketing, and Medical Affairs at Transkaryotic Therapies. Additionally, during his 15-year tenure with Genetics Institute/Wyeth, John held senior-level positions in research and development, manufacturing, and commercial operations, during which time he built what has become a >$1B global pharmaceutical business in hematology. Following the acquisition of Genetics Institute by Wyeth he held senior-level positions in U.S. and global marketing at Wyeth, where he successfully launched four products in three different therapeutic areas (hematology, oncology, and immunology). Currently, John serves as executive chairman of F-star and ImmuneXcite. He started his career at Genzyme (pre-IPO), working in research and development. John received his M.B.A. from Boston University (class valedictorian) and his B.S. in Chemical Engineering from the University of Massachusetts at Amherst.